Unity Biotechnology Inc.

0.99
0.01 (0.64%)
At close: Apr 25, 2025, 3:59 PM
0.97
-1.53%
After-hours: Apr 25, 2025, 04:43 PM EDT

Unity Biotechnology Statistics

Share Statistics

Unity Biotechnology has 17.21M shares outstanding. The number of shares has increased by 0.46% in one year.

Shares Outstanding 17.21M
Shares Change (YoY) 0.46%
Shares Change (QoQ) 0.1%
Owned by Institutions (%) 1.66%
Shares Floating 15.55M
Failed to Deliver (FTD) Shares 943
FTD / Avg. Volume 0.54%

Short Selling Information

The latest short interest is 704.78K, so 4.18% of the outstanding shares have been sold short.

Short Interest 704.78K
Short % of Shares Out 4.18%
Short % of Float 4.22%
Short Ratio (days to cover) 2.48

Valuation Ratios

The PE ratio is -0.63 and the forward PE ratio is -1.15. Unity Biotechnology's PEG ratio is 0.01.

PE Ratio -0.63
Forward PE -1.15
PS Ratio 0
Forward PS 0.1
PB Ratio 2.53
P/FCF Ratio -0.79
PEG Ratio 0.01
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Unity Biotechnology.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 2.62, with a Debt / Equity ratio of 3.03.

Current Ratio 2.62
Quick Ratio 2.62
Debt / Equity 3.03
Debt / EBITDA -0.63
Debt / FCF -0.94
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $0
Profits Per Employee $-1.62M
Employee Count 16
Asset Turnover 0
Inventory Turnover n/a

Taxes

Income Tax 0
Effective Tax Rate 0%

Stock Price Statistics

The stock price has increased by -33.11% in the last 52 weeks. The beta is 1.3, so Unity Biotechnology's price volatility has been higher than the market average.

Beta 1.3
52-Week Price Change -33.11%
50-Day Moving Average 1.44
200-Day Moving Average 1.46
Relative Strength Index (RSI) 37.68
Average Volume (20 Days) 175.41K

Income Statement

Revenue n/a
Gross Profit 0
Operating Income -31.17M
Net Income -25.99M
EBITDA -31.17M
EBIT n/a
Earnings Per Share (EPS) -1.54
Full Income Statement

Balance Sheet

The company has 7.58M in cash and 19.71M in debt, giving a net cash position of -12.13M.

Cash & Cash Equivalents 7.58M
Total Debt 19.71M
Net Cash -12.13M
Retained Earnings -510.34M
Total Assets 37.66M
Working Capital 15.01M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -20.86M and capital expenditures 0, giving a free cash flow of -20.86M.

Operating Cash Flow -20.86M
Capital Expenditures 0
Free Cash Flow -20.86M
FCF Per Share -1.24
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

UBX does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for UBX is $4, which is 304% higher than the current price. The consensus rating is "Buy".

Price Target $4
Price Target Difference 304%
Analyst Consensus Buy
Analyst Count 2
Stock Forecasts

Stock Splits

The last stock split was on Oct 20, 2022. It was a backward split with a ratio of 1:10.

Last Split Date Oct 20, 2022
Split Type backward
Split Ratio 1:10

Scores

Altman Z-Score -20.9
Piotroski F-Score 2